Scarica l'app Stockscreener
0.3861
5.52%
-0.0249
Precedente Chiudi:
$0.411
Aprire:
$0.401
Volume 24 ore:
40,574
Relative Volume:
0.16
Capitalizzazione di mercato:
$9.04M
Reddito:
-
Utile/perdita netta:
$-14.58M
Rapporto P/E:
-0.3357
EPS:
-1.15
Flusso di cassa netto:
$-9.80M
1 W Prestazione:
+4.07%
1M Prestazione:
+3.08%
6M Prestazione:
-71.24%
1 anno Prestazione:
-84.77%
Intervallo 1D:
$0.385
$0.401
Intervallo di 1 settimana:
$0.375
$0.4532
Portata 52W:
$0.30
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Nome
Acurx Pharmaceuticals Inc
Settore
Industria
Telefono
917-533-1469
Indirizzo
259 LIBERTY AVENUE, STATEN ISLAND
Confronta ACXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.3851 | 8.63M | 0 | -14.58M | -9.80M | -1.15 |
|
ONC
Beigene Ltd Adr
|
239.47 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.90 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.17 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.58 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus
Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling StockholderSEC Filing - marketscreener.com
Q2 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment - MSN
ACXP: Acurx Pharmaceuticals Receives 'Buy' Rating from HC Wainwr - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock - Investing.com Australia
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 T - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock By Investing.com - Investing.com India
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 Target | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports Improved Q1 2025 Results - TipRanks
Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million - marketscreener.com
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement - TipRanks
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - Seeking Alpha
Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results - TradingView
Acurx Pharmaceuticals to Reveal Q1 2025 Financial Performance and Key Pipeline Updates - Stock Titan
Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - Yahoo Finance
Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada
Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com
Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan
Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - standard-journal.com
Press Release Distribution & PR Platform - ACCESS Newswire
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Issues Positive Forecast for ACXP Earnings - Defense World
FY2029 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress - TipRanks
Earnings call transcript: Acurx Pharmaceuticals Q4 2024 sees narrower EPS loss - Investing.com Canada
ACXP stock touches 52-week low at $0.43 amid market challenges - Investing.com UK
Acurx Pharmaceuticals, Inc Full Year Loss Narrows - Nasdaq
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Yahoo Finance
Earnings Scheduled For March 18, 2025 - Benzinga
Acurx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Increases By 112.2% - The AM Reporter
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP - Milton Daily Standard
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx Pharmaceuticals Inc Azioni (ACXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
3.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):